Three long-term winning stocks for the post-pandemic world
Professional investor Zehrid Osmani of the Martin Currie Global Portfolio Trust picks three companies with sustainable business models, strong pricing power and a low risk of disruption.
As we come out of the pandemic, we are identifying numerous structural-growth opportunities in several key areas. This comes as governments deploy sizeable fiscal stimuli to support the economic recovery.
These target global infrastructure programmes, which could create attractive long-term opportunities in sectors such as green infrastructure, robotics and automation, and healthcare infrastructure. Green infrastructure developments focus on renewable energy, electric transportation, energy efficiency and greener buildings.
Robotics and automation trends should accelerate, with companies making their manufacturing capacities and supply chains more resilient. Healthcare infrastructure is likely to be channelled into upgrading physical care facilities and extending digitalisation to improve patient care.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The latter implies more remote patient monitoring and virtual care. We seek out firms with sustainable franchises, strong pricing power, low risk of disruption, high returns on invested capital (a key gauge of profitability) and strong balance sheets.
The fifth utility
Sweden’s Atlas Copco (Stockholm: ATCOA) is a global leader in vacuum and air-compressor technologies. Its high market share permits the company to maintain a pricing premium. Atlas Copco is very well run and has shown resilience despite being exposed to cyclical end-markets. What’s more, historically it has managed to cover its cost of capital even during severe recessions.
The group sells to a broad range of customers. Air compressors are known as the “fifth utility’” as they are crucial in sectors such as cars, construction and semiconductors. Atlas Copco is well-placed to harness global infrastructure growth through exposure to green-building construction, renewable energy and infrastructure developments for electric transportation, as well as to 5G and healthcare infrastructure.
Another Swedish company we hold is digital industrial-equipment specialist Hexagon (Stockholm: HEXAB). It focuses on enabling firms to augment their robotics and automation throughout their production lines.
This also has the benefit of helping companies reduce their carbon footprints over time. Hexagon is especially exposed to the structural-growth opportunity from the emergence of “digital twin” assets, which are the digital representations of physical objects such as manufacturing sites.
These digital representations are then used to monitor and improve the performance of the equivalent physical asset. We see several markets moving towards the convergence of digital and physical assets, which bodes well for Hexagon’s revenue growth and profitability over the long term.
Software for bespoke healthcare
US-based Veeva Systems (NYSE: VEEV) is at the forefront of bringing tailored software to drug development: it offers cloud-based solutions for the global life-sciences industry. Veeva’s market opportunity is growing thanks to the trend towards more complex and personalised healthcare. Veeva serves a regulated market with products that provide high barriers to entry against potential competitors, thus giving it the ability to sustain a long period of strong growth and profitability.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Barclays begins paying up to £100 compensation to customers after banking outage
Barclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
By Daniel Hilton Published
-
Review: Shangri-La Paris – an ode to the world’s best food
Natasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
By Natasha Langan Published
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore Published
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves Published
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published